Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study

Chang Yun Yoon; Yung Ly Kim; Seung Hyeok Han; Tae Hyun Yoo; Su Ah Sung; Woo kyung Chung; Dong Wan Chae; Yong Soo Kim; Curie Ahn; Kyu Hun Choi

doi:10.1186/s13098-016-0191-z

Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study

Chang Yun Yoon, Yung Ly Kim, Seung Hyeok Han, Tae Hyun Yoo, Su Ah Sung, Woo kyung Chung, Dong Wan Chae, Yong Soo Kim, Curie Ahn, Kyu Hun Choi

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit behind diverse complications. Adiponectin is known to have anti-atherogenic and cardio-protective effects. Meanwhile, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic syndrome in patients with chronic kidney disease. Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were collected from 1332 patients with chronic kidney disease. Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log adiponectin was positively associated with high-density lipoprotein cholesterol levels (β = 0.006), whereas it was negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C-reactive protein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898-0.970, P < 0.001) after adjustment for multiple confounding factors. Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in patients with chronic kidney disease.

Original language	English
Pages (from-to)	1-10
Number of pages	10
Journal	Diabetology and Metabolic Syndrome
Volume	8
Issue number	1
DOIs	https://doi.org/10.1186/s13098-016-0191-z
Publication status	Published - 2016 Nov 14

Bibliographical note

Funding Information:
The authors acknowledge all of the patients who participated in the KNOW‑ CKD and the investigators who took part in data collection. This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600). The KNOW-CKD Investigator Group Patient Recruitment. Seoul National University Hospital, Curie Ahn, MD (PI), Kook‑Hwan Oh, MD (SubPI), Hajeong Lee, MD, Seungmi Lee, RN, Jiseon Kim, RN, and Aram Lee, RN. Seoul National University Bundang Hospital, Dong Wan Chae, MD (SubPI), Seon Ha Baek MD, and Hyun Jin Cho, RN. Yonsei University, Severance Hospital, Kyu Hun Choi, MD (SubPI), Seung Hyeok Han, MD, Tae Hyun Yoo, MD, and Mi Hyun Yu, RN. Kangbuk Samsung Hospital, Kyu‑Beck Lee, MD and Young Youl Hyun, MD. The Catholic University of Korea, Seoul St. Mary’s Hospital, Yong‑Soo Kim, MD and Min Jung Ahn, RN. Gachon University, Gil Hospital, Wookyung Chung, MD, Ji Yong Jung, MD, Youkyoung Jang, RN, and Ji Hye Park, RN. Eulji Medical Center, Eulji

Publisher Copyright:
© 2016 The Author(s).

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1186/s13098-016-0191-z

Cite this

@article{2fcc88779a3f4467b6122fd11359c080,

title = "Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study",

abstract = "Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit behind diverse complications. Adiponectin is known to have anti-atherogenic and cardio-protective effects. Meanwhile, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic syndrome in patients with chronic kidney disease. Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were collected from 1332 patients with chronic kidney disease. Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log adiponectin was positively associated with high-density lipoprotein cholesterol levels (β = 0.006), whereas it was negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C-reactive protein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898-0.970, P < 0.001) after adjustment for multiple confounding factors. Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in patients with chronic kidney disease.",

author = "Yoon, {Chang Yun} and Kim, {Yung Ly} and Han, {Seung Hyeok} and Yoo, {Tae Hyun} and Sung, {Su Ah} and Chung, {Woo kyung} and Chae, {Dong Wan} and Kim, {Yong Soo} and Curie Ahn and Choi, {Kyu Hun}",

note = "Funding Information: The authors acknowledge all of the patients who participated in the KNOW‑ CKD and the investigators who took part in data collection. This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600). The KNOW-CKD Investigator Group Patient Recruitment. Seoul National University Hospital, Curie Ahn, MD (PI), Kook‑Hwan Oh, MD (SubPI), Hajeong Lee, MD, Seungmi Lee, RN, Jiseon Kim, RN, and Aram Lee, RN. Seoul National University Bundang Hospital, Dong Wan Chae, MD (SubPI), Seon Ha Baek MD, and Hyun Jin Cho, RN. Yonsei University, Severance Hospital, Kyu Hun Choi, MD (SubPI), Seung Hyeok Han, MD, Tae Hyun Yoo, MD, and Mi Hyun Yu, RN. Kangbuk Samsung Hospital, Kyu‑Beck Lee, MD and Young Youl Hyun, MD. The Catholic University of Korea, Seoul St. Mary{\textquoteright}s Hospital, Yong‑Soo Kim, MD and Min Jung Ahn, RN. Gachon University, Gil Hospital, Wookyung Chung, MD, Ji Yong Jung, MD, Youkyoung Jang, RN, and Ji Hye Park, RN. Eulji Medical Center, Eulji Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = nov,

day = "14",

doi = "10.1186/s13098-016-0191-z",

language = "English",

volume = "8",

pages = "1--10",

journal = "Diabetology and Metabolic Syndrome",

issn = "1758-5996",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease

T2 - results from the KNOW-CKD study

AU - Yoon, Chang Yun

AU - Kim, Yung Ly

AU - Han, Seung Hyeok

AU - Yoo, Tae Hyun

AU - Sung, Su Ah

AU - Chung, Woo kyung

AU - Chae, Dong Wan

AU - Kim, Yong Soo

AU - Ahn, Curie

AU - Choi, Kyu Hun

N1 - Funding Information: The authors acknowledge all of the patients who participated in the KNOW‑ CKD and the investigators who took part in data collection. This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600). The KNOW-CKD Investigator Group Patient Recruitment. Seoul National University Hospital, Curie Ahn, MD (PI), Kook‑Hwan Oh, MD (SubPI), Hajeong Lee, MD, Seungmi Lee, RN, Jiseon Kim, RN, and Aram Lee, RN. Seoul National University Bundang Hospital, Dong Wan Chae, MD (SubPI), Seon Ha Baek MD, and Hyun Jin Cho, RN. Yonsei University, Severance Hospital, Kyu Hun Choi, MD (SubPI), Seung Hyeok Han, MD, Tae Hyun Yoo, MD, and Mi Hyun Yu, RN. Kangbuk Samsung Hospital, Kyu‑Beck Lee, MD and Young Youl Hyun, MD. The Catholic University of Korea, Seoul St. Mary’s Hospital, Yong‑Soo Kim, MD and Min Jung Ahn, RN. Gachon University, Gil Hospital, Wookyung Chung, MD, Ji Yong Jung, MD, Youkyoung Jang, RN, and Ji Hye Park, RN. Eulji Medical Center, Eulji Publisher Copyright: © 2016 The Author(s).

PY - 2016/11/14

Y1 - 2016/11/14

N2 - Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit behind diverse complications. Adiponectin is known to have anti-atherogenic and cardio-protective effects. Meanwhile, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic syndrome in patients with chronic kidney disease. Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were collected from 1332 patients with chronic kidney disease. Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log adiponectin was positively associated with high-density lipoprotein cholesterol levels (β = 0.006), whereas it was negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C-reactive protein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898-0.970, P < 0.001) after adjustment for multiple confounding factors. Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in patients with chronic kidney disease.

AB - Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit behind diverse complications. Adiponectin is known to have anti-atherogenic and cardio-protective effects. Meanwhile, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic syndrome in patients with chronic kidney disease. Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were collected from 1332 patients with chronic kidney disease. Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log adiponectin was positively associated with high-density lipoprotein cholesterol levels (β = 0.006), whereas it was negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C-reactive protein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898-0.970, P < 0.001) after adjustment for multiple confounding factors. Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in patients with chronic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=84994745309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994745309&partnerID=8YFLogxK

U2 - 10.1186/s13098-016-0191-z

DO - 10.1186/s13098-016-0191-z

M3 - Article

AN - SCOPUS:84994745309

VL - 8

SP - 1

EP - 10

JO - Diabetology and Metabolic Syndrome

JF - Diabetology and Metabolic Syndrome

SN - 1758-5996

IS - 1

ER -

Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this